Keyphrases
Multiple Myeloma
100%
Bortezomib
100%
18F-fluorodeoxyglucose (18F-FDG)
100%
P(LLA-CL)
100%
Assessment of Therapeutic Response
100%
VLA-4
57%
MM.1S
42%
Tumor
28%
Flow Cytometry
28%
Myeloma Cells
28%
Bioluminescence Imaging
28%
CD49d
28%
SUVmean
28%
U266
28%
Treatment Group
14%
Improved Outcomes
14%
Bone Marrow
14%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
14%
Green Fluorescent Protein
14%
Therapeutic Response
14%
Total-body
14%
High-level Expression
14%
Inoculation
14%
Spine
14%
Tumor Progression
14%
Luciferase
14%
Plasma Cells
14%
Dynamic PET
14%
Femur
14%
In Vivo Assessment
14%
Multiple Myeloma Patients
14%
CD29
14%
Treatment Change
14%
NOD-SCID
14%
Molar Activity
14%
U266 Cells
14%
Medicine and Dentistry
Treatment Response
100%
Fluorodeoxyglucose F 18
100%
Multiple Myeloma
100%
Copper 64
100%
Bortezomib
100%
Polyethylene Terephthalate
100%
Neoplasm
28%
Flow Cytometry
28%
Myeloma Cell
28%
Bioluminescence
28%
Positron Emission Tomography
14%
In Vitro
14%
Ex Vivo
14%
Green Fluorescent Protein
14%
Radioactive Tracer
14%
Tumor Progression
14%
Luciferase
14%
Immunoglobulin Producing Cell
14%
Diseases
14%
Treatment Group
14%
Neuroscience
In Vivo
100%
Positron Emission Tomography
100%
Fluorine-18
100%
Bortezomib
100%
Bioluminescence
50%
Flow Cytometry
50%
Positron Emission Tomography
25%
In Vitro
25%
Luciferase
25%
Vertebral Column
25%
Green Fluorescent Protein
25%
CD29
25%
Immunoglobulin Producing Cell
25%
Pharmacology, Toxicology and Pharmaceutical Science
Bortezomib
100%
Multiple Myeloma
100%
Fluorodeoxyglucose F 18
100%
Copper 64
100%
Polyethylene Terephthalate
100%
Neoplasm
28%
Flow Cytometry
28%
Tumor Growth
14%
Luciferase
14%
Tracer
14%
Green Fluorescent Protein
14%
NOD SCID Gamma Mouse
14%
Diseases
14%
Treatment Group
14%
Immunology and Microbiology
Multiple Myeloma
100%
Myeloma Cell
28%
CD49d
28%
Bioluminescence
28%
Positron Emission Tomography
14%
CD29
14%
NSG Mouse
14%
Immunoglobulin Producing Cell
14%
Vertebral Column
14%